title: Comparison of Moisturizing Creams for the Prevention of Atopic Dermatitis Relapse: A Randomized Double-blind Controlled Multicentre Clinical Trial.
abstract: Atopic dermatitis (AD) affects adults and children and has a negative impact on quality of life. The present multicentre randomized double-blind controlled trial showed a barrier-improving cream (5% urea) to be superior to a reference cream in preventing eczema relapse in patients with AD (hazard ratio 0.634, p = 0.011). The risk of eczema relapse was reduced by 37% (95% confidence interval (95% CI) 10-55%). Median time to relapse in the test cream group and in the reference cream group was 22 days and 15 days, respectively (p = 0.013). At 6 months 26% of the patients in the test cream group were still eczema free, compared with 10% in the reference cream group. Thus, the barrier-improving cream significantly prolonged the eczema-free time compared with the reference cream and decreased the risk of eczema relapse. The test cream was well tolerated in patients with AD.
authors.affiliation: Department of Innovation, ACO Hud Nordic AB, SE- 194 26 Upplands Väsby, Sweden.
authors.forename: Ulf
authors.initials: U
authors.lastname: Åkerström
authors.forename: Sakari
authors.initials: S
authors.lastname: Reitamo
authors.forename: Tor
authors.initials: T
authors.lastname: Langeland
authors.forename: Mats
authors.initials: M
authors.lastname: Berg
authors.forename: Lisbeth
authors.initials: L
authors.lastname: Rustad
authors.forename: Laura
authors.initials: L
authors.lastname: Korhonen
authors.forename: Marie
authors.initials: M
authors.lastname: Lodén
authors.forename: Karin
authors.initials: K
authors.lastname: Wirén
authors.forename: Mats
authors.initials: M
authors.lastname: Grände
authors.forename: Petra
authors.initials: P
authors.lastname: Skare
authors.forename: Åke
authors.initials: Å
authors.lastname: Svensson
mesh_terms: D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018592:Cross-Over Studies; D003876:Dermatitis, Atopic / Q000175:diagnosis* / Q000188:drug therapy* / Q000523:psychology; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004311:Double-Blind Method; D004643:Emollients / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D011446:Prospective Studies; D011788:Quality of Life; D012008:Recurrence; D018570:Risk Assessment; D055502:Secondary Prevention / Q000379:methods; D012720:Severity of Illness Index; D013548:Sweden; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D003879:Dermatologic Agents; D004643:Emollients